INVO Bioscience (INVO) Competitors $2.20 +0.17 (+8.37%) As of 04/25/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock INVO vs. PYPD, NMTC, NEPH, RVP, NXGL, ADGM, GBS, XAIR, VVOS, and PETVShould you be buying INVO Bioscience stock or one of its competitors? The main competitors of INVO Bioscience include PolyPid (PYPD), NeuroOne Medical Technologies (NMTC), Nephros (NEPH), Retractable Technologies (RVP), NEXGEL (NXGL), Adagio Medical (ADGM), GBS (GBS), Beyond Air (XAIR), Vivos Therapeutics (VVOS), and PetVivo (PETV). These companies are all part of the "surgical & medical instruments" industry. INVO Bioscience vs. PolyPid NeuroOne Medical Technologies Nephros Retractable Technologies NEXGEL Adagio Medical GBS Beyond Air Vivos Therapeutics PetVivo PolyPid (NASDAQ:PYPD) and INVO Bioscience (NASDAQ:INVO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability. Does the MarketBeat Community believe in PYPD or INVO? PolyPid received 25 more outperform votes than INVO Bioscience when rated by MarketBeat users. Likewise, 80.00% of users gave PolyPid an outperform vote while only 46.67% of users gave INVO Bioscience an outperform vote. CompanyUnderperformOutperformPolyPidOutperform Votes3280.00% Underperform Votes820.00% INVO BioscienceOutperform Votes746.67% Underperform Votes853.33% Do insiders and institutionals have more ownership in PYPD or INVO? 26.5% of PolyPid shares are owned by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 3.5% of INVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor PYPD or INVO? In the previous week, PolyPid had 2 more articles in the media than INVO Bioscience. MarketBeat recorded 3 mentions for PolyPid and 1 mentions for INVO Bioscience. PolyPid's average media sentiment score of 0.30 beat INVO Bioscience's score of 0.00 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral INVO Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate PYPD or INVO? PolyPid currently has a consensus price target of $11.33, indicating a potential upside of 331.58%. Given PolyPid's stronger consensus rating and higher possible upside, equities research analysts plainly believe PolyPid is more favorable than INVO Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25INVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, PYPD or INVO? PolyPid has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Which has higher valuation and earnings, PYPD or INVO? INVO Bioscience has higher revenue and earnings than PolyPid. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolyPidN/AN/A-$29.02M-$4.97-0.53INVO Bioscience$5.77M1.45-$8.03MN/AN/A Is PYPD or INVO more profitable? PolyPid has a net margin of 0.00% compared to INVO Bioscience's net margin of -122.79%. INVO Bioscience's return on equity of 0.00% beat PolyPid's return on equity.Company Net Margins Return on Equity Return on Assets PolyPidN/A -624.10% -129.28% INVO Bioscience -122.79%N/A -36.94% SummaryPolyPid beats INVO Bioscience on 11 of the 16 factors compared between the two stocks. Get INVO Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for INVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INVO vs. The Competition Export to ExcelMetricINVO BioscienceSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.38M$4.33B$5.46B$7.81BDividend YieldN/A46.43%5.43%4.26%P/E RatioN/A30.7422.4318.48Price / Sales1.4553.00391.42101.49Price / CashN/A51.0838.1834.62Price / Book-1.076.146.684.19Net Income-$8.03M$68.15M$3.22B$248.18M7 Day Performance14.58%4.65%6.25%6.54%1 Month Performance-8.71%-6.33%-2.70%-1.97%1 Year Performance124.49%28.36%16.86%4.72% INVO Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INVOINVO BioscienceN/A$2.20+8.4%N/A+124.5%$8.38M$5.77M0.0025News CoveragePYPDPolyPid2.1088 of 5 stars$2.75+0.4%$11.33+312.1%-44.7%$28.03MN/A-0.5580Short Interest ↑NMTCNeuroOne Medical Technologies0.6336 of 5 stars$0.57-2.2%N/A-42.3%$26.87M$5.75M-2.1820Short Interest ↑Gap UpNEPHNephros2.6531 of 5 stars$1.97-1.5%$5.00+153.8%-8.2%$20.88M$14.16M-21.8930Short Interest ↓Positive NewsRVPRetractable TechnologiesN/A$0.69-1.1%N/A-29.9%$20.66M$33.05M-1.28240NXGLNEXGEL1.5376 of 5 stars$2.54-10.2%N/A+14.5%$19.44M$8.69M-4.3810Short Interest ↓Gap DownADGMAdagio MedicalN/A$1.20-32.6%N/AN/A$18.46M$266,000.000.0087High Trading VolumeGBSGBSN/A$1.19-0.8%N/A-47.8%$17.72M$440,000.00-2.127XAIRBeyond Air4.4191 of 5 stars$0.23-3.5%$3.67+1,485.9%-81.3%$15.91M$3.02M-0.2270News CoverageHigh Trading VolumeVVOSVivos Therapeutics2.7675 of 5 stars$2.20+4.8%$6.10+177.3%+1.5%$12.96M$15.03M-0.39160Short Interest ↓Positive NewsGap DownPETVPetVivoN/A$0.52-6.4%N/A-29.3%$12.59M$1.05M-1.1620News Coverage Related Companies and Tools Related Companies PolyPid Competitors NeuroOne Medical Technologies Competitors Nephros Competitors Retractable Technologies Competitors NEXGEL Competitors Adagio Medical Competitors GBS Competitors Beyond Air Competitors Vivos Therapeutics Competitors PetVivo Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INVO) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
